Cost-Effectiveness Analysis of Antibiotic Therapy for Community-Acquired Pneumonia at Mimika Regional Hospital, Central Papua
Abstract
Background: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide, affecting the lower respiratory tract. It is caused by diverse pathogens, including bacteria, viruses, fungi, and chemical exposures. Antibiotics, such as ceftriaxone, are widely used for treatment. However, the high economic burden associated with CAP management necessitates a cost-effectiveness analysis to optimize treatment strategies.Objectives: This study aimed to evaluate the cost-effectiveness of three antibiotic regimens—co-amoxiclav, meropenem + levofloxacin, and ceftriaxone—for CAP inpatients at Mimika Hospital, Indonesia, to identify the most efficient therapeutic option.Methods: A retrospective, cross-sectional observational study was conducted using medical records of CAP patients admitted to Mimika Hospital between January and December 2021. Inclusion criteria were patients aged ≥18 years who received a single antibiotic regimen. Treatment effectiveness was assessed based on hospitalization duration (≤3 days) and physician-reported recovery. Cost-effectiveness was evaluated using the Average Cost-Effectiveness Ratio (ACER).Results: A total of 120 pneumonia inpatients were analyzed, predominantly male (60%) and aged 26–45 years (34%). The most frequently administered antibiotic was ceftriaxone (51%), followed by co-amoxiclav (29%) and meropenem + levofloxacin (20%). Co-amoxiclav demonstrated the highest clinical effectiveness (88.57%) and the lowest median…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.